Clinical Trial Update: PR-018: An Open-Label, Safety Extension of Study PR-011 [Phase 4]

View source ↗

Summary

Open-label safety extension of study PR-011 (PR-018) in Cystic Fibrosis with Exocrine Pancreatic Insufficiency; Phase 4 completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis
• Exocrine Pancreatic Insufficiency

Drugs mentioned

• PR-011
• PR-018

Snippet

Sponsor: Forest Laboratories | Conditions: Cystic Fibrosis, Exocrine Pancreatic Insufficiency | Phase 4 | Status: COMPLETED | Results posted: 2014-03-07